Mode
Text Size
Log in / Sign up

MITF E318K variant associated with significantly increased melanoma risk and high nevus burdenSpecific gene variant linked to higher risk of multiple melanomas

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize MITF E318K as a moderate-penetrance allele associated with increased melanoma risk and multiple primaries.

This systematic review and meta-analysis evaluates the clinical implications of the MITF E318K variant in individuals with germline MITF variants. The analysis included 8,606 melanoma patients and 17,953 controls to determine the association between the variant and melanoma risk, as well as associated conditions like renal cancer and pheochromocytoma/paraganglioma.

The meta-analysis found that the MITF E318K variant is associated with a significantly increased melanoma risk (OR 2.55; 95% CI 1.90-3.43), with a prevalence of 2.1% in patients versus 0.8% in controls. A stronger association was observed in patients with multiple primary melanomas (OR up to 4.45). Additionally, the variant was associated with high nevus burden (OR up to 12.4) in multiple cohorts.

Findings regarding non-melanoma cancers were less consistent. While one study reported an increased risk of renal cancer (OR 7.64), this was not replicated in larger cohorts. An association with pheochromocytoma/paraganglioma (OR 3.19) was observed but lacks confirmation. The authors note that evidence for these non-melanoma cancers is limited and heterogeneous. No consistent association was found regarding age at onset or pigmentary traits. The MITF E318K variant is characterized as a moderate-penetrance melanoma susceptibility allele, particularly linked to multiple primary melanomas.

How this fits prior evidence

This meta-analysis identifies the MITF E318K variant as a moderate-penetrance melanoma susceptibility allele. While the study does not directly address the mechanisms of immunotherapy resistance, the role of immunoediting, or the efficacy of specific treatments like the Encorafenib and Binimetinib combination or nivolumab-containing regimens, it provides genetic context for melanoma risk and susceptibility. The finding of increased risk for multiple primary melanomas may be relevant for patients undergoing the treatments mentioned in prior coverage.

For people with a family history of skin cancer, understanding genetic risk is a vital piece of the puzzle. Researchers analyzed data from over 8,000 melanoma patients to see how specific genes influence cancer risk. They found that a specific genetic variant, known as MITF E318K, is strongly associated with an increased risk of melanoma.

This risk is even more pronounced for those who develop multiple primary melanomas. The study also noted a very strong link between this variant and a high number of moles, which is often a sign of increased skin risk. While the study looked into other types of cancer, like renal cancer or pheochromocytoma, the evidence for those specific links was not consistent or confirmed across different groups.

It is important to note that while this variant shows a clear link to melanoma, it did not show a consistent connection to the age at which cancer starts or a person's skin color. Because the evidence for other cancer types was limited and varied, the strongest takeaway remains the specific link between the MITF E318K variant and melanoma risk.

What this means for you:
The MITF E318K genetic variant is linked to a higher risk of melanoma, especially for multiple primary cases.

Common questions

What is the MITF E318K variant?

The MITF E318K variant is a specific genetic change that can influence a person's risk for certain types of cancer. In this study, it was identified as a moderate-penetrance allele, meaning it is associated with a significantly increased risk of melanoma, particularly for those who develop multiple primary melanomas.

Does this variant affect other types of cancer?

The study looked at other conditions like renal cancer and pheochromocytoma or paraganglioma. While some initial reports showed a link, these results were not confirmed in larger groups. Because the evidence for these other cancers was limited and inconsistent, the link to melanoma is the most clear finding.

Does the variant affect skin color or the age of cancer onset?

No, the study found no consistent association between the MITF E318K variant and a person's pigmentary traits or the age at which melanoma first appears. The primary findings focused on the risk of cancer and the number of moles, known as nevus burden, rather than physical traits or timing.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
The MITF E318K variant has been associated with melanoma risk, while risk associated with other variants or of other cancers remains uncertain. We performed a systematic review with meta-analysis of 11 retrospective case-control studies to evaluate cancer risks associated with germline MITF variants. Across 8,606 melanoma patients and 17,953 controls, the E318K variant was detected in 2.1% and 0.8% of individuals, respectively, corresponding to a significantly increased melanoma risk (OR 2.55, 95% CI 1.90-3.43). The association was stronger in patients with multiple primary melanomas, with carrier frequencies up to 2.6% compared to 1.0% in single melanoma cases and ORs reaching 4.45 in individual studies. Phenotypic analyses showed enrichment of high nevus burden (> 200 nevi), with ORs up to 12.4 in multiple melanoma cohorts. No consistent association with age at onset or pigmentary traits was observed. Evidence for non-melanoma cancers was limited and heterogeneous: a single study reported increased renal cancer risk (OR 7.64), whereas larger cohorts failed to replicate this finding; an association with pheochromocytoma/paraganglioma was observed (OR 3.19) but lacks confirmation. No other MITF variants demonstrated significant cancer risk. These findings support MITF E318K as a moderate-penetrance melanoma susceptibility allele, particularly associated with multiple primary melanomas.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.